Fulcrum Therapeutics Inc

General ticker "FULC" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $246.2M

Fulcrum Therapeutics Inc does not follow the US Stock Market performance with the rate: -24.1%.

Estimated limits based on current volatility of 5.8%: low 4.16$, high 4.68$

Factors to consider:

  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [4.29$, 10.12$]
  • 2024-12-30 to 2025-12-30 estimated range: [4.21$, 9.82$]

Financial Metrics affecting the FULC estimates:

  • Negative: Non-GAAP EPS, $ of -1.58 <= 0.10
  • Negative: Operating profit margin, % of -97.53 <= 1.03
  • Negative: Operating cash flow per share per price, % of -22.31 <= 2.35
  • Negative: negative Net income
  • Negative: Inventory ratio change, % of 1.28 > 1.08
  • Positive: -0.96 < Investing cash flow per share, $ of -0.60

Similar symbols

Short-term FULC quotes

Long-term FULC plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $19.16MM $6.34MM $2.81MM
Operating Expenses $100.22MM $118.90MM $113.47MM
Operating Income $-81.05MM $-112.56MM $-110.66MM
Non-Operating Income $0.21MM $2.69MM $13.33MM
R&D Expense $69.70MM $76.78MM $71.80MM
Income(Loss) $-80.85MM $-109.87MM $-97.33MM
Profit(Loss) $-80.85MM $-109.87MM $-97.33MM
Stockholders Equity $211.54MM $198.94MM $235.19MM
Inventory $0.47MM $0.85MM $0.00MM
Assets $235.00MM $226.69MM $257.69MM
Operating Cash Flow $-78.48MM $-97.05MM $-90.97MM
Capital expenditure $1.71MM $1.96MM $0.51MM
Investing Cash Flow $-129.67MM $12.41MM $-36.69MM
Financing Cash Flow $186.51MM $84.32MM $118.12MM
Earnings Per Share* $-2.22 $-2.35 $-1.59

* EPS are Split Adjusted, recent splits may be reflected with a delay.